Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04067297

Using Big Data to Conduct Innovative Cardiovascular Clinical Trials

Traditional randomized clinical trials (RCTs) have provided extremely valuable information on medical therapies and procedures that have changed the way heart diseases are treated. However, despite these contributions, traditional RCTs are costly, the findings may not be applicable to patients unlike those in the study, and the use of trial findings may be infrequent. These limitations may be addressed by incorporating 'big data' in RCTs, which is the emerging field using electronic information that is routinely collected in various large administrative health databases. The Community Heart Outcomes Improvement and Cholesterol Education Study (CHOICES) will test the potential of using 'big data' in a 'real-world' clinical trial to measure outcomes using routinely collected health information. CHOICES aims to increase the use of cholesterol-lowering statin drugs to prevent heart attack and stroke in high-risk health regions across Ontario using a 'toolbox' of interventions. The 'toolbox' of interventions are informational strategies targeted for both patients and family physicians to help improve cholesterol management and contribute to shared decision making for heart healthy goals.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

40 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

ICES

Toronto, Ontario, M4N3M5, Canada

About this study

An estimated 19,500 cardiac events could be prevented each year in Canada by use of statin therapy as recommended in the Canadian Cardiovascular Society's Lipid Guidelines. Despite substantial evidence supporting statin use, several studies suggest dyslipidemia management in Canada remains suboptimal. In Ontario, prior work using the 2008 Cardiovascular Health in Ambulatory Care Research Team (CANHEART) 'big data' registry of almost the entire Ontario population of 9.8 million adults created through linkage of 17+ population health databases at ICES, has documented an approximate 2-fold variation across the province in cardiovascular events that is associated with performance of key cardiovascular preventive measures, particularly lipid screening and statin prescribing. This work noted that the variation did not have a clear association with traditional clinical risk factors or socioeconomic conditions. This observation suggests that heterogeneity in this care process may be modifiable with an intervention geared to improving adherence to national guidelines.

In this pragmatic, cluster randomized registry trial, 'big data' is used to test the 'real world' effectiveness of a tailored, multicomponent intervention strategy aimed at improving lipid management (screening, risk assessment, statin initiation, statin adherence) amongst a primary prevention cohort of 40 to 75 year olds individuals living in 14 (of 28) communities in Ontario with higher than average rates of cardiovascular events. A multicomponent intervention strategy will include a 'toolbox' of lipid management resources for both patient and physicians in the intervention (high-risk) communities of the province. The intervention strategy will include tools to enable patients and physicians to make informed and shared decisions about statin therapy and will be implemented in the intervention communities using targeted local and social media strategies. Patient characteristics for those aged 40 to 75 and clinical outcomes in this study will be measured without primary data collection using the 2016 CANHEART 'big data' registry, with the exception of stain use and adherence data available only in adults 66 to 75 years old.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Community with CVD incidence rates higher than the Ontario provincial average
  • Community with a population size greater than 5,000 40 to 75 year olds
  • Community with at least 1,000 66 to 75 year olds
  • Community with 20 to 130 active and practicing family physicians

Exclusion criteria

  • Patients with established CVD within each community

Treatment and study plan

Lipid management toolbox

Other

The intervention toolbox will include: 1) community-level report cards on lipid management (developed using an updated version of the 2016 CANHEART 'big data' registry of ~10.9 million adults created through linkage of 19+ population health databases) to distribute to family physicians, 2) printed and electronic patient education materials on cholesterol screening and management, 3) a new online clinical decision aid to facilitate shared decision-making between patients and their family physicians regarding statin utilization, 3) patient educational videos, and 4) physician educational videos and material.

Primary outcomes

  1. Number of 66 -75 year old patients who filled a statin prescription

    Time frame: 3 years

    Proportion of FRS determined intermediate- and high-risk residents (aged 66 to 75) in each community who filled a statin prescription within 100 days, as measured by the CANHEART registry at the completion of the 3 year intervention period.

Secondary outcomes

  1. Number of lipid-related visits to primary care physicians

    Time frame: 3 years

    The number of lipid-related visits to primary care physicians for the primary prevention cohort of 40 to 75 year olds in each community.

  2. Number of 66-75 year old patients who adhered to a statin prescription

    Time frame: 3 years

    Adherence rates to statins in FRS determined intermediate- and high-risk statin users 66 to 75 year olds in each community. Adherence will be measured at 1.2 times the prescription length.

  3. Rate of 40-75 year old patients receiving lipid screening

    Time frame: 3 years

    Proportion of 40 to 75 year olds in the primary prevention cohort for each community receiving lipid screening from lab data.

  4. Incidence of Acute Myocardial Infarction (AMI), stroke or CVD death (major CVD outcome)

    Time frame: 3 years

    The proportion of AMI, stroke or CVD death in the primary prevention cohort of 40 to 75 year olds in each community, along with the individual components of these incident composite outcomes.

  5. Incidence of revascularization procedures, AMI, stroke, or CVD death (general CVD outcome)

    Time frame: 3 years

    The proportion of AMI, stroke, or CVD death in addition to revascularization procedures in the primary prevention cohort of 40 to 75 year olds in each community, along with the individual components of these incident composite outcomes.

  6. Incidence of Diabetes Mellitus (DM)

    Time frame: 3 years

    The incident rates of DM in 40 to 75 year olds in the primary prevention cohort of 40 to 75 year olds in each community.

Sponsors and collaborators

Lead sponsor

Institute for Clinical Evaluative Sciences

Other

Collaborators

  • CorHealth Ontario
  • Heart & Stroke Richard Lewar Centres of Excellence in Cardiovascular Research
  • Heart and Stroke Foundation of Ontario
  • The Ontario Spor Support Unit
  • Unity Health Toronto

Registry information

Official study title

Using Big Data to Conduct Innovative Cardiovascular Clinical Trials: The Community Heart Outcomes Improvement and Cholesterol Education Study (CHOICES)

Important dates

Study start
2019
Primary completion
2027
Study completion
2027
First posted
Aug 26, 2019
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.